Bictegravir + emtricitabine + tenofovir alafenamide
Bictegravir + emtricitabine + tenofovir alafenamide has been studied in 3 papers since 2024: 3 observational studies in people; 1 in the past year. The newest paper, Feb 20, 2026: “Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort”.
See all 3 papers on bictegravir + emtricitabine + tenofovir alafenamide
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“and an increase of +0.3 with BIC ( P = 0.013)”
None of its findings points the other way.
- 1 lab in 1 country
- Humans3
What did studies of bictegravir + emtricitabine + tenofovir alafenamide find?
2Studies of bictegravir + emtricitabine + tenofovir alafenamide measured 2 outcomes: SCORE2 and METS-IR.
SCORE2
upin humans1
1 study
SCORE2
upin humans1
Bictegravir + emtricitabine + tenofovir alafenamide is linked with higher SCORE2 in humans (people with HIV) (+0.30).
Humanspeople with HIV48 weeks
METS-IR
upin humans1
1 study
METS-IR
upin humans1
Bictegravir + emtricitabine + tenofovir alafenamide is linked with higher METS-IR in humans (people with HIV) (+0.3).
Humanspeople with HIV48 weeks